Provention Bio Inc (NASDAQ:PRVB) Director Anthony Digiandomenico acquired 4,442 shares of the firm’s stock in a transaction dated Monday, December 3rd. The shares were purchased at an average cost of $2.45 per share, for a total transaction of $10,882.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Anthony Digiandomenico also recently made the following trade(s):
- On Friday, November 30th, Anthony Digiandomenico acquired 5,000 shares of Provention Bio stock. The shares were purchased at an average cost of $2.45 per share, for a total transaction of $12,250.00.
- On Monday, November 26th, Anthony Digiandomenico acquired 10,000 shares of Provention Bio stock. The shares were purchased at an average cost of $2.65 per share, for a total transaction of $26,500.00.
Shares of PRVB opened at $2.21 on Friday. Provention Bio Inc has a 1 year low of $2.02 and a 1 year high of $8.00.
A hedge fund recently bought a new stake in Provention Bio stock. Vanguard Group Inc. purchased a new stake in shares of Provention Bio Inc (NASDAQ:PRVB) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 712,902 shares of the company’s stock, valued at approximately $2,859,000. Vanguard Group Inc. owned 2.10% of Provention Bio as of its most recent filing with the SEC. 2.51% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This story was first published by WKRB News and is the sole property of of WKRB News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.wkrb13.com/2018/12/08/insider-buying-provention-bio-inc-prvb-director-purchases-4442-shares-of-stock.html.
About Provention Bio
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.
Recommended Story: Do stock splits help investors?
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.